| CAS NO: | 530-62-1 |
| 包装: | 100g |
| 市场价: | 525元 |
| Cas No. | 530-62-1 |
| 别名 | N,N'-羰基二咪唑 |
| 化学名 | di(imidazol-1-yl)methanone |
| Canonical SMILES | C1=CN(C=N1)C(=O)N2C=CN=C2 |
| 分子式 | C7H6N4O |
| 分子量 | 162.15 |
| 溶解度 | Soluble in water or 1% acetic acid |
| 储存条件 | Desiccate at -20℃ |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | IC50: Not available. The common method of peptide synthesis is not feasible for industry use due to its poor yields. CDI, a new peptide forming reagent, is applied recently as a more direct agent for the formation of acyl-imidazoles. [1] In vitro: CDI can be prepared straightforwardly by the reaction of phosgene with four equivalents of imidazole under anhydrous conditions. It served as a convenient reagent for peptide synthesis since its side products, carbon dioxide and imidazole, were safe. Moreover, the carbon dioxide evolution was suggested to provide driving force for the peptide synthesis. A typical peptide-formation reaction was started by dissolving 0.010 mole acylamino acid in 10 ml tetrahydrofuran (THF), and after this, the evolution of carbon dioxide could be immediately observed. An hour later, the required amino acid or peptide ester was added with an amount of 0.010 molar. The reaction would be last for 15 min, but longer standing is probably beneficial. The formed peptide was then purified by wiping off the solvent under vacuum followed by washing the residue with acid, saturated bicarbonate and finally water.[1] In vivo: So far, no in vivo data has been reported. Clinical trial: So far, no clinical trial has been conducted. Reference: |
m.cnreagent.com